Predictive value of pentraxin-3 on disease severity and prognosis in patients with hemorrhagic fever with renal syndrome

Hong Du  
Second Affiliated Hospital of Air Force Medical University

Haifeng Hu  
Second Affiliated Hospital of Air Force Medical University  
https://orcid.org/0000-0002-5870-7450

Pingzhong Wang  
Second Affiliated Hospital of Air Force Medical University

Xiaoyan Wang  
Second Affiliated Hospital of Air Force Medical University

Ying Zhang  
Second Affiliated Hospital of Air Force Medical University

Hong Jiang  
Second Affiliated Hospital of Air Force Medical University

Jing Li  
Second Affiliated Hospital of Air Force Medical University

Xuefan Bai  
Second Affiliated Hospital of Air Force Medical University

Jianqi Lian (lianjq@fmmu.edu.cn)  
Second Affiliated Hospital of Air Force Medical University

Research article

Keywords: hemorrhagic fever with renal syndrome, pentraxin-3, early prediction, prognosis, disease severity

DOI: https://doi.org/10.21203/rs.3.rs-30998/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Pentraxin-3 is an acute-phase protein involved in the processes of inflammatory and infection. This study aimed to analyze the changes of plasma pentraxin-3 prospectively and evaluate its predictive value on disease severity and prognosis in patients with hemorrhagic fever with renal syndrome (HFRS).

Methods

105 patients with HFRS admitted by the Second Affiliated Hospital of Air Force Medical University from October 2012 to December 2014 were randomly enrolled in this study. All patients were divided into a mild-type group (17 cases), a moderate-type group (27 cases), a severe-type group (26 cases) and a critical-type group (35 cases) according to the HFRS criteria for clinical classification. 96 venous blood samples of acute phase and 65 of convalescent phase were collected from patients during hospitalization, while venous blood samples of 27 healthy volunteers were taken as controls. The levels of plasma pentraxin-3 were detected using the enzyme linked immunosorbent assay (ELISA), and which were compared among the acute and convalescent phases in different types of patients, as well as the control group. Spearman correlation analysis was used to evaluate the correlation between pentraxin-3 and conventional laboratory parameters. The predictive effectiveness for prognosis of pentraxin-3 was evaluated by receiver operating characteristic (ROC) curve analysis.

Results

There was no significant difference in gender and age distribution between all types of patients and control group (P > 0.05). In all types of patients, the levels of pentraxin-3 in acute phase were significantly higher than that of control group and convalescent phase of the same type (P < 0.05). The levels of pentraxin-3 increased with the aggravation of the disease, and showed the highest expression in critical-type patients (P < 0.05). Pentraxin-3 was positively correlated with WBC, AST and APTT, and negatively correlated with PLT, ALB and Fib (|r_s| > 0.500, P < 0.001). Pentraxin-3 showed significant predictive value for the prognosis of patients with HFRS, with the area under ROC curve (AUC) of 0.753 (95% CI: 0.593 ~ 0.914, P = 0.003).

Conclusions

The detection of plasma pentraxin-3 can be beneficial to the evaluation of disease severity and prognosis in patients with HFRS.
Hemorrhagic fever with renal syndrome (HFRS) is a kind of natural focus disease caused by Hantavirus infection, which is characterized by fever, hemorrhage and renal impairment [1]. Hantavirus infection could induce the destruction of vascular endothelial cells [2], the diffuse damage of systemic microvessels, the increase of capillary permeability, and the decrease of platelets [3]. Patients with intemperate immunoreaction may further develop “capillary leakage syndrome”, which could result in secondary edema, hypovolemic shock, acute kidney injury (AKI), coagulation disorder, and even multiple organ dysfunction syndrome (MODS) [4]. It has been accepted that HFRS has immunopathological features of systemic inflammatory response syndrome (SIRS) [5]. The early diagnosis and disease severity assessment may help the clinicians to choose the best therapeutic schedule for patients and finally improve the therapeutic effect of patients with HFRS [6]. Given the limited predictive value of conventional laboratory parameters, it is necessary to explore novel biomarkers for disease severity and prognosis in patients with HFRS.

As the first long-pentraxin discovered by human, pentraxin-3 is mainly produced by monocyte macrophages and myeloid dendritic cells stimulated by pro-inflammatory signals such as IL-1β, TNF-α and Toll-like receptor activation, as well as the secretion of neutrophils, lymphocytes, and endothelial cells [7]. Pentraxin-3 plays an important role in innate humoral immune response, inflammatory response, anti-infection, as well as tissue damage and repair [8]. Many previous studies have shown that the level of plasma pentraxin-3 is positively related to the severity of sepsis, acute pancreatitis, acute myocardial injury and other diseases, which can be severed as a new biomarker for inflammation, infection and tissue damage [9–13]. Additionally, the over-expressed pentraxin-3 of neutrophils may be associated with the overproduction of reactive oxygen species (ROS) and vascular endothelial dysfunction, and which may represent an emerging biomarker for the progression of vascular injury in patients with hemodialysis [14]. Laine et al [15] showed that plasma pentraxin-3 was highly correlated with PLT, Fib, APTT and other coagulation indicators in patients with acute Puumala virus infection, and which got a favorable predictive value for the severity of epidemic nephropathy patients. However, the role of pentraxin-3 in HFRS caused by Hantaan virus infection has not been reported. Given the above research background, we prospectively analyzed the changes of plasma pentraxin-3 in patients with HFRS, and investigated its predictive value for disease severity and prognosis (death) of HFRS.

**Methods**

**Study Population**

105 patients with HFRS admitted by the Second Affiliated Hospital of Air Force Medical University from October 2012 to December 2014 were randomly enrolled in this study. All patients were confirmed by serological examination with the positive results of specific IgM and IgG antibodies against Hantaan virus in the acute phase. The assay was performed using IgM/IgG capture ELISA kits and was analyzed via a multifunctional autoanalyzer (BIORAD-680, United States). Patients with chronic kidney diseases, diabetes, cardiovascular diseases, hematological diseases, autoimmune diseases, viral hepatitis and other liver diseases were excluded. Data of demographic, laboratory and clinical outcomes were reviewed
Procedures and Definitions

According to the clinical classification criteria of HFRS [16], all enrolled patients were divided into the following four groups: (1) mild-type: patients with mild renal impairment without oliguria and hypotension; (2) moderate-type: patients with obvious symptoms of effusion (bulbar conjunctiva), hypotension, hemorrhage (skin and mucous membranes), and AKI with a typical oliguria stage; (3) severe-type: patients with severe uremia, effusion (bulbar conjunctiva and either peritoneum or pleura), hemorrhage (skin and mucous membranes), hypotension, and AKI with oliguria (urine output 100 ~ 500 mL/day) ≤ 5 days or anuria (urine output < 100 mL/day) ≤ 2 days; (4) critical-type: patients with one or more of the following complications compared with the severe-type patients: refractory shock (≥ 2 days), visceral hemorrhage, heart failure, pulmonary edema, brain edema, severe secondary infection, and severe AKI with either oliguria (urine output 100 ~ 500 mL/day) > 5 days or anuria (urine output < 100 mL/day) > 2 days. The classification of all patients was confirmed by their attending physicians respectively. Based on the classically defined five stages of HFRS [17], the clinical course was divided into the acute phase (including the febrile, hypotensive, and oliguric stages) and the convalescent phase (including the diuretic and convalescent stages). The patients received a follow-up visit until 28 days after discharge, and the death in this study was defined as patient died during hospitalization or the follow-up period.

Blood samples and the detection of pentraxin-3

Under sterile conditions, 96 venous blood samples in acute phase and 65 in convalescent phase from the enrolled patients, and 27 from healthy volunteers were collected by ethylene diamine tetraacetic acid (EDTA) tubes. All specimens were collected on an empty stomach in the morning, and were centrifuged at 3000 rpm for 10 min at 4 °C within 2 hours after drawing. The plasma supernatant was pipetted carefully and transferred to polypropylene tubes and then stored at −80 °C prior to analysis. To avoid the experimental errors caused by repeated freeze-thaw of plasma, all specimens were tested together after collection.

Pentraxin-3 levels were measured with commercially available ELISA kits (Quantikine, XiTang, Inc., Shanghai, China) and were tested using a multifunctional autoanalyzer (BIORAD-680, United States) according to the manufacturer’s instructions. Each sample was detected in duplicate and the sensitivity of the minimum concentration of pentraxin-3 was between 0.008 ng/ml and 0.116 ng/mL. According to the difference of clinical typing, some samples of the patients were further taken multiple dilutions according to 1:2, 1:4, 1:16, 1:32 and 1:64, and finally selected the reasonable detection results.
### Statistical analysis

Continuous variables of normal distribution and non-normal distribution were presented as mean ± standard deviation and median (interquartile range) respectively, and were compared by one-way analysis of variance (one-way ANOVA) and Kruskal-Wallis H test, respectively. The categorical variables were presented as numbers (percentage) and compared by chi-square test. The levels of pentraxin-3 in acute phase and convalescent phase were compared by Wilcoxon matched-pairs signed-ranks test. Spearman correlation analysis was used to evaluate the correlation between pentraxin-3 and conventional laboratory parameters. The predictive efficacy of pentraxin-3 for the prognosis (death) of patients with HFRS was evaluated by the receiver operating characteristic (ROC) curve analysis and quantified by the area under the ROC curve (AUC). A two-sided $P < 0.05$ was considered statistically significant. All statistical analyses were performed using SPSS software (IBM SPSS Statistics, version 23.0).

### Results

#### Clinical typing and demographic characteristics of the enrolled patients

There were a total of 105 patients with a mean age of $41.85 \pm 15.35$ years enrolled in this study, including 21 (20.0%) females and 84 (80.0%) males. According to the grouping criteria mentioned above, 17 cases were classified as mild-type, 27 cases were classified as moderate-type, 26 cases were classified as severe-type, and 35 cases were classified as critical-type. Of all the enrolled patients, 14 (13.3%) critical patients were died and the rest were recovered and discharged. There was no significant difference in gender and age distribution between all types of patients and control group ($P > 0.05$) (Table 1).

#### Table 1

Demographic characteristics of patients with HFRS and healthy controls

|                | Mild-type ($n = 17$) | Moderate-type ($n = 27$) | Severe-type ($n = 26$) | Critical-type ($n = 35$) | Healthy controls ($n = 27$) |
|----------------|----------------------|--------------------------|------------------------|--------------------------|-----------------------------|
| **Gender**     |                      |                          |                        |                          |                             |
| Female         | 6 (35.3%)            | 5 (18.5%)                | 3 (11.5%)              | 7 (20.0%)                | 6 (22.2%)                   |
| Male           | 11 (64.7%)           | 22 (81.5%)               | 23 (88.5%)             | 28 (80.0%)               | 21 (77.8%)                  |
| **Age, years**| $36.47 \pm 17.14$    | $40.07 \pm 13.67$        | $43.62 \pm 12.96$      | $44.51 \pm 15.09$        | $40.65 \pm 13.16$          |

*a* Categorical variables were presented as numbers (percentage) and compared by chi-square test; $\chi^2 = 3.690$, $P = 0.450$.

*b* Continuous variables were presented as mean ± standard deviation and compared by one-way ANOVA; $F = 1.419$, $P = 0.242$. 
Levels of plasma pentraxin-3 in patients with HFRS

In all types of patients, the levels of pentraxin-3 in acute phase were significantly higher than that of control group and convalescent phase of the same type (\(P<0.05\)). The levels of pentraxin-3 had an increasing tendency with the aggravation of the disease, and showed the highest expression in critical-type patients (\(P<0.05\)). The comparison of pentraxin-3 during the convalescent phase among the four types demonstrated no significant difference (\(P<0.05\)) (Table 2 and Fig. 1).

### Table 2
Levels of pentraxin-3 in patients with HFRS

|                  | Mild-type   | Moderate-type | Severe-type | Critical-type | Healthy controls |
|------------------|-------------|---------------|-------------|---------------|------------------|
| Pentraxin-3, ng/mL |             |               |             |               |                  |
| **Acute phase**  | 58.21 (22.84 - 334.37) | 216.13 (63.61 - 539.01) | 171.07 (51.28 - 458.82) | 570.30 (138.37 - 1088.51) | 0.46 (0.18 - 0.65) |
| **Convalescent phase** | 2.52 (1.25 - 11.19) | 11.30 (5.64 - 26.90) | 5.87 (3.14 - 8.00) | 4.92 (2.49 - 11.34) |                  |

\(a\) The levels of pentraxin-3 in acute phase were compared by Kruskal-Wallis H test; \(H = 69.128, P < 0.001\).

\(b\) The levels of pentraxin-3 in convalescent phase were compared by Kruskal-Wallis H test; \(H = 56.540, P < 0.001\).

The correlation between pentraxin-3 and conventional laboratory parameters

The results of spearman correlation analysis showed that pentraxin-3 was positively correlated with WBC, AST and APTT, and negatively correlated with PLT, ALB and Fib (\(|r_s|>0.500, P < 0.001\)) (Table 3 and Fig. 2).
Table 3  
Spearman correlation analysis between pentraxin-3 and conventional laboratory parameters

| Conventional laboratory parameters | Pentraxin-3, ng/mL | rs     | P value |
|-----------------------------------|--------------------|--------|---------|
| WBC, ×10^9/L                      |                    | 0.636  | < 0.001 |
| PLT, ×10^9/L                      |                    | -0.797 | < 0.001 |
| HGB, g/L                          |                    | 0.385  | < 0.001 |
| HCT, %                            |                    | 0.265  | 0.001   |
| ALB, g/L                          |                    | -0.578 | < 0.001 |
| ALT, U/L                          |                    | 0.303  | < 0.001 |
| AST, U/L                          |                    | 0.681  | < 0.001 |
| PT, sec                           |                    | 0.155  | 0.065   |
| PTA, %                            |                    | -0.134 | 0.112   |
| APTT, sec                         |                    | 0.629  | < 0.001 |
| Fib, g/L                          |                    | -0.583 | < 0.001 |
| BUN, mmol/L                       |                    | 0.203  | 0.010   |
| Cr, µmol/L                        |                    | -0.040 | 0.618   |
| UA, µmol/L                        |                    | -0.214 | 0.006   |

Abbreviations: \( r_s \), coefficient of rank correlation; WBC, white blood cells; PLT, platelets; HGB, hemoglobin; HCT, hematocrit; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; PTA, prothrombin activity; APTT, activated partial thromboplastin time; Fib, fibrinogen; BUN, blood urea nitrogen; Cr, creatinine; UA, uric acid; sec, second.

**Predictive efficacy of pentraxin-3 for the prognosis (death) in patients with HFRS**

The results of ROC curve analysis demonstrated obvious predictive value of pentraxin-3 for the prognosis (death) of patients with HFRS, and which with the AUC of 0.753 (95% CI: 0.593 ~ 0.914, \( P = 0.003 \)). The sensitivity and specificity of pentraxin-3 for predicting the prognosis (death) was 71.4% and 80.5%, respectively (Table 4 and Fig. 3).
Table 4
Predictive efficacy of pentraxin-3 and conventional laboratory parameters

|                      | AUC (95% CI) | P value | Cut-off value | Sensitivity | Specificity |
|----------------------|--------------|---------|---------------|-------------|-------------|
| Pentraxin-3, ng/mL   | 0.753 (0.593 - 0.914) | 0.003   | 569.088       | 71.4%       | 80.5%       |
| WBC, ×10⁹/L          | 0.742 (0.573 - 0.911)  | 0.004   | 31.525        | 57.1%       | 93.9%       |
| PLT, ×10⁹/L          | 0.747 (0.621 - 0.872)  | 0.003   | 41.5          | 47.6%       | 92.9%       |
| ALB, g/L             | 0.732 (0.553 - 0.911)  | 0.006   | 24.85         | 81.7%       | 71.4%       |
| AST, U/L             | 0.883 (0.787 - 0.979)  | < 0.001 | 203           | 78.6%       | 90.9%       |
| APTT, sec            | 0.865 (0.747 - 0.984)  | < 0.001 | 54.55         | 64.3%       | 96.2%       |
| Fib, g/L             | 0.824 (0.710 - 0.937)  | < 0.001 | 1.8425        | 86.1%       | 71.4%       |
| Cr, µmol/L           | 0.534 (0.391 - 0.677)  | 0.686   | -             | -           | -           |
| BUN, mmol/L          | 0.536 (0.359 - 0.712)  | 0.670   | -             | -           | -           |

Abbreviations: AUC, area under the ROC curve; CI, confidence interval; WBC, white blood cells; PLT, platelets; ALB, albumin; AST, aspartate aminotransferase; APTT, activated partial thromboplastin time; Fib, fibrinogen; Cr, creatinine; BUN, blood urea nitrogen; sec, second.

Discussion

After infection with Hantavirus, the human body could develop a strong and rapid immune response characterized by the hyperactivity of immune cells and the flooding of cytokines, so as to the damage of vascular endothelium and visceral organs [1–6]. As one of the most important immune cells in innate immunity, neutrophils play a crucial part in resisting bacterial infection. Nevertheless, the neutrophil counts are also elevated in most patients with HFRS triggered by the Hantavirus infection, and which are also positively correlated with the disease severity of HFRS [16, 18]. Therefore, neutrophils may also play an important role in the immunopathological injury of HFRS. Pentraxin-3 synthesized by neutrophils is mainly stored in neutrophil granules, which can interact with a variety of bacteria, fungi and viruses after release and then propel the phagocytosis and clearance of pathogenic microorganisms [19]. As an important component of innate humoral immunity, pentraxin-3 has the ability to bind complement component C1q and then activate the classical pathway of complement [20, 21]. Recently, many studies have showed that pentraxin-3 could modulate inflammatory cells, interact with P-selectin, reduce the nitric oxide (NO) synthesis of endothelial cells, inhibit endothelial cells proliferation and alter their functions,
and finally promote vascular inflammatory response and endothelial dysfunction [22, 23]. Therefore, the release of pentraxin-3 by neutrophil degranulation may be an important link in the immunopathological injury of HFRS, and the level of plasma pentraxin-3 may indirectly reflect the severity of vascular endothelial injury in patients with HFRS.

In present study, the results have showed that the levels of pentraxin-3 in acute phase were significantly higher than that of control group and convalescent phase of the same type, and had an increasing tendency with the aggravation of HFRS. In addition, the level of plasma pentraxin-3 was highly correlated with WBC, PLT, AST, ALB, APTT, Fib and other conventional laboratory parameters, which is consistent with the findings of pentraxin-3 in epidemic nephropathy [15]. The above findings indicate that pentraxin-3 can serve as an early predictor for the disease severity of HFRS. The results of ROC curves analysis demonstrated the significant predictive value of pentraxin-3 for the prognosis (death) of patients with HFRS, which was comparable with the predictive value of conventional laboratory parameters such as PLT. Therefore, pentraxin-3 could serve as a novel and efficient biomarker for predicting the disease severity and prognosis of patients with HFRS. The detection of plasma pentraxin-3 may help clinicians quickly identify the severe patients at an early stage and timely take optimal therapeutic schedule for them, so as to improve the therapeutic effect of patients with HFRS.

As an observational prospective study, although we got a meaningful conclusion that the detection of plasma pentraxin-3 might be beneficial to evaluating the disease severity and prognosis of the HFRS patients, while there were still some limitations as following: First, this study was conducted in a single center for infectious diseases. The results might be limited by the relatively small sample size because of the gradually declining incidence of HFRS in Xi’an city. Because some patients had tided over the acute phase on admission and only convalescence samples available, and the dead patients had died before entering the convalescence phase, so in fact, only 96 venous blood specimens in acute phase and 65 in convalescence phase were collected from patients during hospitalization. All these adverse factors may affect the accuracy of the research results. Second, the definition of blood sample collection time of HFRS patients was too broad in this study. Given to the individual differences of patients’ condition and the clinical process on admission, we could only randomly collect venous blood specimens according to the acute phase and convalescence phase defined in the study. Although there was no significant statistical difference in the median collection time of all samples in the acute phase, the level of plasma pentraxin-3 was also influenced by the different time-points and the variability of pathological injury during the acute phase of Hantaan virus infection. Third, it is essential to conduct a prospective, large sample, multicenter cohort study to further confirm the predictive efficacy and clinical application value of plasma pentraxin-3 in acute phase. Last but not least, the research limitations caused by the experimental measurement errors and outdated clinical typing criteria should not be overlooked.

Conclusions

The detection of plasma pentraxin-3 might be beneficial to the evaluation of disease severity and prognosis in patients with HFRS, which could help clinicians quickly identify the severe patients at an
early stage and timely take optimal therapeutic schedule for them, so as to improve the therapeutic effect of patients with HFRS.

**Abbreviations**

HFRS: Hemorrhagic fever with renal syndrome; AKI: Acute kidney injury; MODS: Multiple organ dysfunction syndrome; SIRS: Systemic inflammatory response syndrome; ROS: Reactive oxygen species; EDTA: Ethylene diamine tetraacetic acid; ELISA: Enzyme linked immunosorbent assay; ANOVA: Analysis of variance; ROC curve: Receiver operating characteristic curve; AUC: Area under the ROC curve; WBC: White blood cells; PLT: Platelet; AST: Aspartate aminotransferase; ALB: Albumin; APTT: Activated partial thromboplastin time; Fib: Fibrinogen.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the ethics committee of the Second Affiliated Hospital of Air Force Medical University and was performed in accordance with the Helsinki Declaration. Before inclusion, the patients and healthy volunteers were informed about the objectives of this study, and they or their guardians agreed and signed the informed consent form.

**Consent for publication**

Written informed consents were obtained from all patients or their guardians and the healthy volunteers.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was funded by the National Science and Technology Major Project (grant number 2017ZX10204401-002-005); the Key Clinical Research Project of Technology Innovation and Development Foundation in the Second Affiliated Hospital of Air Force Medical University (grant number
2019LCYJ002); and the General Clinical Research Project of Technology Innovation and Development Foundation in the Second Affiliated Hospital of Air Force Medical University (grant number 2019LCYJ011). The funders had no role in the design and conduct of the study.

Authors' contributions

JQL and XFB conceived and designed the study and had full access to all of the data in the study, and they take responsibility for the integrity of the data and the accuracy of the data analysis. HD, XYW and JL collected the venous blood samples and detected the levels of plasma pentraxin-3 using the ELISA test. HFH and XYW collected the clinical data of all enrolled patients. HFH and HD conducted the statistical analysis and manuscript drafting. PZW, YZ, HJ, XFB and JQL reviewed the manuscript and made critical revision. All authors have made substantial contributions to this study, and all of them read and approved the final manuscript.

Acknowledgements

We acknowledge all the enrolled patients and healthy volunteers, and also the health-care workers involved in the diagnosis and treatment of patients with HFRS.

References

1. Avšič-Županc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect. 2019;21S:e6–16.
2. Mackow ER, Gavrilovskaya IN. Hantavirus regulation of endothelial cell functions. Thromb Haemost. 2009;102:1030–41.
3. Mittler E, Dieterle ME, Kleinfelter LM, Slough MM, Chandran K, Jangra RK. Hantavirus entry: perspectives and recent advances. Adv Virus Res. 2019;104:185–224.
4. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Mäkelä S, et al. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol. 2013;11:539–50.
5. 10.3390/v11070601 Garanina E, Martynova E, Davidyuk Y, Kabwe E, Ivanov K, Titova A, et al. Cytokine Storm Combined with Humoral Immune Response Defect in Fatal Hemorrhagic Fever with Renal Syndrome Case, Tatarstan, Russia. Viruses. 2019; doi: 10.3390/v11070601.
6. Jiang H, Du H, Wang LM, Wang PZ, Bai XF. Hemorrhagic Fever with Renal Syndrome: Pathogenesis and Clinical Picture. Front Cell Infect Microbiol. 2016;6:1.
7. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev. 2009;227:9–18.
8. Garlanda C, Jaillon S, Doni A, Bottazzi B, Mantovani A. PTX3, a humoral pattern recognition molecule at the interface between microbe and matrix recognition. Curr Opin Immunol. 2016;38:39–44.

9. Albert Vega C, Mommert M, Boccard M, Rimmelé T, Venet F, Pachot A, et al. Source of Circulating Pentraxin 3 in Septic Shock Patients. Front Immunol. 2018;9:3048.

10. Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019;19:968.

11. Ninomiya I, Kanazawa M, Umemura M, Onodera O. Elevated serum pentraxin 3 levels might predict the diagnosis of branch atheromatous disease at a very early stage. Eur J Neurol. 2020. doi:10.1111/ene.14249.

12. Lee YT, Gong M, Chau A, Wong WT, Bazoukis G, Wong SH, et al. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis. J Infect. 2018;76:1–10.

13. Zagidullin N, Motloch LJ, Gareeva D, Hamitova A, Lakman I, Krioni I, et al. Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J Clin Med. 2020. doi:10.3390/jcm9020550.

14. dell’Oglio MP, Simone S, Ciccone M, Corciulo R, Gesualdo M, Zito A, et al. Neutrophil-dependent pentraxin-3 and reactive oxygen species production modulate endothelial dysfunction in haemodialysis patients. Nephrol Dial Transplant. 2017;32:1540–9.

15. Laine OK, Koskela SM, Outinen TK, Joutsi-Korhonen L, Huhtala H, Vaheri A, et al. Plasma pentraxin-3 and coagulation and fibrinolysis variables during acute Puumala hantavirus infection and associated thrombocytopenia. Blood Coagul Fibrinolysis. 2014;25:612–7.

16. Du H, Li J, Yu HT, Jiang W, Zhang Y, Wang JN, et al. Early indicators of severity and construction of a risk model for prognosis based upon laboratory parameters in patients with hemorrhagic fever with renal syndrome. Clin Chem Lab Med. 2014;52:1667–75.

17. Zhang C, Tang K, Zhang Y, Ma Y, Zhuang R, Zheng X, et al. Elevated Plasma Growth Arrest-Specific 6 Protein Levels Are Associated with the Severity of Disease During Hantaan Virus Infection in Humans. Viral Immunol. 2017;30:330–5.

18. Strandin T, Mäkelä S, Mustonen J, Vaheri A. Neutrophil Activation in Acute Hemorrhagic Fever With Renal Syndrome Is Mediated by Hantavirus-Infected Microvascular Endothelial Cells. Front Immunol. 2018;9:2098.

19. Razvina O, Jiang S, Matsubara K, Ohashi R, Hasegawa G, Aoyama T, et al. Differential expression of pentraxin 3 in neutrophils. Exp Mol Pathol. 2015;98:33–40.

20. Daigo K, Inforzato A, Barajon I, Garlanda C, Bottazzi B, Meri S, et al. Pentraxins in the activation and regulation of innate immunity. Immunol Rev. 2016;274:202–17.

21. Haapasalo K, Meri S. Regulation of the Complement System by Pentraxins. Front Immunol. 2019;10:1750.
22. Carrizzo A, Lenzi P, Procaccini C, Damato A, Biagioni F, Ambrosio M, et al. Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway. Circulation. 2015;131:1495–505.

23. Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;91:163–79.

**Figures**

**Figure 1**

Levels of plasma pentraxin-3 during the clinical course in patients with HFRS The levels of plasma pentraxin-3 in acute phase (A) and convalescent phase (B) were compared by Kruskal-Wallis H test; pairwise comparisons among the five groups were performed using the Nemenyi rank test. The differences of plasma pentraxin-3 between acute phase and convalescent phase of the mild-type (C1), the moderate-type (C2), the severe-type (C3), and the critical-type (C4) were compared by Wilcoxon matched-pairs signed-ranks test. * P<0.05
Figure 2

The correlation between pentraxin-3 and conventional laboratory parameters. Figure shows the correlation between pentraxin-3 and WBC (A), PLT (B), ALB (C), AST (D), APTT (E), Fib (F). Spearman rank correlation analysis was used to evaluate the correlation between pentraxin-3 and conventional laboratory parameters. Abbreviations: WBC, White blood cells; PLT, Platelet; AST, Aspartate aminotransferase; ALB, Albumin; APTT, Activated partial thromboplastin time; Fib, Fibrinogen.
Figure 3

ROC curves for evaluating the predictive efficacy of pentraxin-3 and conventional laboratory parameters. The figure shows the predictive efficacy of pentraxin-3, AST, PLT, WBC, and ALB for the prognosis (death) in patients with HFRS. Pentraxin-3 showed significant predictive value, with the AUC of 0.753 (P=0.003).

Abbreviations: ROC curve, Receiver operating characteristic curve; AUC, Area under the ROC curve; WBC, White blood cells; PLT, Platelet; AST, Aspartate aminotransferase; ALB, Albumin